Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.

about

C3 glomerulopathy.Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.De novo glomerular diseases after renal transplantation: How is it different from recurrent glomerular diseases?

P2860

Q39207807-B19270A0-DA49-4F68-AAD8-D6D702272D2F Q42086661-BD6FA3FD-418B-4E23-A3D6-DDE045E069EA Q47172094-A21F40C2-F5B5-47C9-BEAF-DC30BFCC0270

P2860

Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.

Item

http://www.wikidata.org/entity/Q41373365

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Severe active C3 glomeruloneph ...... ated after eculizumab therapy.

@en

type

Item

label

Severe active C3 glomeruloneph ...... ated after eculizumab therapy.

@en

prefLabel

Severe active C3 glomeruloneph ...... ated after eculizumab therapy.

@en

P1476

Severe active C3 glomeruloneph ...... ated after eculizumab therapy.

@en

P2093

Alenka Vizjak

http://www.w3.org/2001/XMLSchema#string

Dušan Ferluga

http://www.w3.org/2001/XMLSchema#string

Jerica Mraz

http://www.w3.org/2001/XMLSchema#string

Nika Kojc

http://www.w3.org/2001/XMLSchema#string

Tanja Kersnik Levart

http://www.w3.org/2001/XMLSchema#string

P2860

Eculizumab for dense deposit disease and C3 glomerulonephritis

Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease)

Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion

Membranoproliferative glomerulonephritis--a new look at an old entity

Eculizumab and Refractory Membranoproliferative Glomerulonephritis

Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries

Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease.

Complement and glomerular disease: new insights.

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.

Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.

P2888

s13000-016-0547-6

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1186/S13000-016-0547-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1039978057

http://www.w3.org/2001/XMLSchema#string

P698

27717365

http://www.w3.org/2001/XMLSchema#string

P921

glomerulonephritis

P932

5055692

http://www.w3.org/2001/XMLSchema#string

Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.

about

P2860

P2860

Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P932